drugset / Trial / NCT05059522
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
Timeline
- Start
- 2021-09-29
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | Oral |
| Subject | Axitinib | Small molecule | — | Oral |
| Subject | CMP-001 | Other / unclassified | — | Other |
| Subject | Ivuxolimab | Monoclonal antibody | — | Intravenous |
| Subject | Lorlatanib | Unknown | — | Oral |
| Subject | Pemetrexed | Small molecule | — | Intravenous |
| Subject | Talazoparib | Small molecule | — | Oral |
| Subject | Utomilumab | Monoclonal antibody | — | Intravenous |